ACRX

AcelRx Pharmaceuticals, Inc. Press Releases

$3.17
*  
0.08
2.46%
Get ACRX Alerts
*Delayed - data as of May 3, 2016  -  Find a broker to begin trading ACRX now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    ACRX Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing



AcelRx Pharmaceuticals Provides Corporate Update and Reports First Quarter 2016 Financial Results
5/2/2016 4:01:00 PM - PR Newswire
▼-2.46 % Price Change since this news event. The Volume Ratio is 0.98.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AcelRx Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Monday, May 2nd, 2016
4/28/2016 7:00:00 AM - PR Newswire
▼-5.93 % Price Change since this news event. The Volume Ratio is 1.89.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AcelRx Pharmaceuticals Names Howard B. Rosen as Chief Executive Officer and Provides Update on Clinical Development Activities and Corporate Priorities for 2016
3/29/2016 4:00:00 PM - PR Newswire
▲0.32 % Price Change since this news event. The Volume Ratio is 1.77.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AcelRx Publishes a Review of Hospital-Based Opioid Patient-Controlled Analgesia, Risks and Pharmacoeconomics
3/25/2016 7:00:00 AM - PR Newswire
▼-0.94 % Price Change since this news event. The Volume Ratio is 0.7.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AcelRx Pharmaceuticals Advances ARX-04 into Extension Phase of Open-Label Phase 3 Emergency Room Study
3/14/2016 7:00:00 AM - PR Newswire
▼-12.43 % Price Change since this news event. The Volume Ratio is 1.78.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AcelRx Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2015 Financial Results
3/7/2016 4:01:00 PM - PR Newswire
▼-20.75 % Price Change since this news event. The Volume Ratio is 1.48.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AcelRx Pharmaceuticals Initiates Phase 3 Study of ARX-04 in Patients with Post-Operative Moderate-to-Severe Acute Pain
3/7/2016 7:00:00 AM - PR Newswire
▼-18.51 % Price Change since this news event. The Volume Ratio is 2.78.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AcelRx Pharmaceuticals to Hold Annual 2015 Financial Results Conference Call and Webcast on Monday, March 7th, 2016.
3/3/2016 7:00:00 AM - PR Newswire
▼-26.45 % Price Change since this news event. The Volume Ratio is 2.93.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AcelRx Pharmaceuticals to Present at Two Upcoming Investor Events in March
3/1/2016 7:00:00 AM - PR Newswire
▼-14.56 % Price Change since this news event. The Volume Ratio is 2.67.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AcelRx Pharmaceuticals' Moderate-to-Severe Acute Pain Candidate ARX-04 Shows Improved Pain Scores in ER Patients in Interim Phase 3 Analysis
2/25/2016 7:00:00 AM - PR Newswire
▼-15.01 % Price Change since this news event. The Volume Ratio is 7.57.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


AcelRx Pharmaceuticals Presents Phase 3 Results from ARX-04 Clinical Program at JAB Burn and Wound Care Symposium
2/11/2016 7:00:00 AM - PR Newswire
▼-6.76 % Price Change since this news event. The Volume Ratio is 10.86.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day